Shenzhen Kangtai Biological Products Co Ltd (300601) - Net Assets
Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) has net assets worth CN¥9.66 Billion CNY (≈ $1.41 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.93 Billion ≈ $2.04 Billion USD) and total liabilities (CN¥4.27 Billion ≈ $624.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shenzhen Kangtai Biological Products Co (300601) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥9.66 Billion |
| % of Total Assets | 69.36% |
| Annual Growth Rate | 26.99% |
| 5-Year Change | 5.07% |
| 10-Year Change | 1210.42% |
| Growth Volatility | 47.03 |
Shenzhen Kangtai Biological Products Co Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Shenzhen Kangtai Biological Products Co stock valuation.
Annual Net Assets for Shenzhen Kangtai Biological Products Co Ltd (2012–2025)
The table below shows the annual net assets of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2025. Also explore how fast is Shenzhen Kangtai Biological Products Co growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.63 Billion ≈ $1.41 Billion |
-0.30% |
| 2024-12-31 | CN¥9.66 Billion ≈ $1.41 Billion |
+1.25% |
| 2023-12-31 | CN¥9.54 Billion ≈ $1.40 Billion |
+6.19% |
| 2022-12-31 | CN¥8.99 Billion ≈ $1.31 Billion |
-1.98% |
| 2021-12-31 | CN¥9.17 Billion ≈ $1.34 Billion |
+22.82% |
| 2020-12-31 | CN¥7.46 Billion ≈ $1.09 Billion |
+170.98% |
| 2019-12-31 | CN¥2.75 Billion ≈ $403.03 Million |
+49.92% |
| 2018-12-31 | CN¥1.84 Billion ≈ $268.83 Million |
+71.53% |
| 2017-12-31 | CN¥1.07 Billion ≈ $156.72 Million |
+45.72% |
| 2016-12-31 | CN¥735.00 Million ≈ $107.55 Million |
+13.58% |
| 2015-12-31 | CN¥647.12 Million ≈ $94.69 Million |
+10.84% |
| 2014-12-31 | CN¥583.81 Million ≈ $85.43 Million |
+56.87% |
| 2013-12-31 | CN¥372.17 Million ≈ $54.46 Million |
-13.69% |
| 2012-12-31 | CN¥431.21 Million ≈ $63.10 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Kangtai Biological Products Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4322.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.13 Billion | 22.09% |
| Other Components | CN¥7.50 Billion | 77.91% |
| Total Equity | CN¥9.63 Billion | 100.00% |
Shenzhen Kangtai Biological Products Co Ltd Competitors by Market Cap
The table below lists competitors of Shenzhen Kangtai Biological Products Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hefei Meiya Optoelectronic Technology Inc
SHE:002690
|
$1.99 Billion |
|
Test Research Inc
TW:3030
|
$1.99 Billion |
|
NGL Energy Partners LP
NYSE:NGL
|
$1.99 Billion |
|
WK Kellogg Co
NYSE:KLG
|
$1.99 Billion |
|
Stagwell Inc
NASDAQ:STGW
|
$1.99 Billion |
|
Ruentex Industries Ltd
TW:2915
|
$1.98 Billion |
|
Dgb Financial
KO:139130
|
$1.98 Billion |
|
Zenas BioPharma, Inc. Common Stock
NASDAQ:ZBIO
|
$1.98 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Kangtai Biological Products Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,661,123,922 to 9,631,743,291, a change of -29,380,631 (-0.3%).
- Net income of 70,330,463 contributed positively to equity growth.
- Dividend payments of 131,552,216 reduced retained earnings.
- Other comprehensive income decreased equity by 3,277,783,693.
- Other factors increased equity by 3,309,624,815.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥70.33 Million | +0.73% |
| Dividends Paid | CN¥131.55 Million | -1.37% |
| Other Comprehensive Income | CN¥-3.28 Billion | -34.03% |
| Other Changes | CN¥3.31 Billion | +34.36% |
| Total Change | CN¥- | -0.30% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Kangtai Biological Products Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 25.81x to 1.41x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.47 | CN¥12.15 | x |
| 2013-12-31 | CN¥0.42 | CN¥12.15 | x |
| 2014-12-31 | CN¥0.70 | CN¥12.15 | x |
| 2015-12-31 | CN¥0.73 | CN¥12.15 | x |
| 2016-12-31 | CN¥0.82 | CN¥12.15 | x |
| 2017-12-31 | CN¥1.09 | CN¥12.15 | x |
| 2018-12-31 | CN¥1.84 | CN¥12.15 | x |
| 2019-12-31 | CN¥2.70 | CN¥12.15 | x |
| 2020-12-31 | CN¥6.94 | CN¥12.15 | x |
| 2021-12-31 | CN¥8.25 | CN¥12.15 | x |
| 2022-12-31 | CN¥8.12 | CN¥12.15 | x |
| 2023-12-31 | CN¥8.53 | CN¥12.15 | x |
| 2024-12-31 | CN¥8.62 | CN¥12.15 | x |
| 2025-12-31 | CN¥8.62 | CN¥12.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Kangtai Biological Products Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.63%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.46x
- Recent ROE (0.73%) is below the historical average (9.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 2.65% | 9.35% | 0.11x | 2.64x | CN¥-31.67 Million |
| 2013 | 0.41% | 0.60% | 0.23x | 2.97x | CN¥-35.71 Million |
| 2014 | 5.34% | 10.27% | 0.23x | 2.30x | CN¥-27.22 Million |
| 2015 | 9.71% | 13.88% | 0.34x | 2.06x | CN¥-1.89 Million |
| 2016 | 11.73% | 15.62% | 0.34x | 2.18x | CN¥12.71 Million |
| 2017 | 20.05% | 18.49% | 0.53x | 2.06x | CN¥107.60 Million |
| 2018 | 23.72% | 21.60% | 0.60x | 1.82x | CN¥251.97 Million |
| 2019 | 20.86% | 29.56% | 0.49x | 1.44x | CN¥299.08 Million |
| 2020 | 9.10% | 30.04% | 0.24x | 1.28x | CN¥-67.16 Million |
| 2021 | 13.78% | 34.59% | 0.26x | 1.54x | CN¥346.70 Million |
| 2022 | -1.48% | -4.20% | 0.23x | 1.53x | CN¥-1.03 Billion |
| 2023 | 9.03% | 24.77% | 0.23x | 1.58x | CN¥-92.86 Million |
| 2024 | 2.09% | 7.60% | 0.18x | 1.51x | CN¥-764.46 Million |
| 2025 | 0.73% | 2.63% | 0.19x | 1.46x | CN¥-892.84 Million |
Industry Comparison
This section compares Shenzhen Kangtai Biological Products Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Kangtai Biological Products Co Ltd (300601) | CN¥9.66 Billion | 2.65% | 0.44x | $1.99 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus ace… Read more